Aloe Spiriti M A, Petti M C, Latagliata R, Avvisati G, De Gregoris C, Proia S, Fazi P, Jaalouk G, Mancini M, Spadea A
Department of Human Biopathology, University La Sapienza, Rome, Italy.
Leuk Lymphoma. 1993 Jan;9(1-2):79-83. doi: 10.3109/10428199309148507.
It has been recently demonstrated that erythropoietin increases the haemoglobin levels in anemia secondary to chronic renal failure. Moreover some recent experiences also suggested a possible role in the treatment of MDS. From April 1990 to April 1992, 23 patients (16 males and 7 females, median age 63.5 years) affected with low risk myelodysplastic syndrome (MDS) were treated with recombinant human erythropoietin (rHuEPO) to ameliorate Hb levels and transfusional requirement. All patients received high doses of rHuEPO (800 U/Kg weekly s.c. in 2-3 divided doses, for 3 months). A complete remission, defined as stable normalization of Hb level, was achieved in 1/23 patients. This patient had refractory anemia, by FAB criteria. A partial response, defined as stable increase of Hb levels > or = 1 g/dl and/or reduction of transfusional requirement > or = 50% lasting at least 3 months, was achieved in 7/23 patients. Patients with a partial response received rHuEPO at increased dosages (1200 U/Kg weekly s.c. 2-3 times): 1/7 achieved a complete response, 4/7 remained stable and 2/7 decreased to pre-therapy Hb value. These results suggest that rHuEPO may be a promising therapeutic tool for some MDS patients.
最近已证实，促红细胞生成素可提高慢性肾衰竭继发性贫血患者的血红蛋白水平。此外，一些近期的经验还表明其在骨髓增生异常综合征（MDS）治疗中可能发挥作用。1990年4月至1992年4月，对23例低危骨髓增生异常综合征（MDS）患者（16例男性，7例女性，中位年龄63.5岁）采用重组人促红细胞生成素（rHuEPO）治疗，以改善血红蛋白水平和输血需求。所有患者均接受高剂量rHuEPO（每周皮下注射800 U/Kg，分2 - 3次给药，共3个月）。1/23例患者达到完全缓解，即血红蛋白水平稳定正常。根据FAB标准，该患者为难治性贫血。7/23例患者达到部分缓解，定义为血红蛋白水平稳定升高≥1 g/dl和/或输血需求减少≥50%，持续至少3个月。部分缓解的患者接受增加剂量的rHuEPO（每周皮下注射1200 U/Kg，2 - 3次）：7例中有1例达到完全缓解，4例保持稳定，2例降至治疗前血红蛋白值。这些结果表明，rHuEPO可能是一些MDS患者有前景的治疗工具。
